Cipla
Focus: Cipla is a generics-focused pharmaceutical manufacturer headquartered in Mumbai with a portfolio spanning infectious diseases, oncology, cardiovascular, hematology, and respiratory therapeutics. The company generates one-third of revenue from a single product (Darunavir), reflecting a mature, high-volume generic business model.
Profile data last refreshed 4h ago · AI intelligence enriched 3d ago
Open Jobs
0
About Cipla
AI assessmentNot HiringNo open roles listed right now. Follow Cipla to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Cipla's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Late-stage
6 Phase 3+
LOE Risk
2 imminent
ALBUTEROL SULFATE
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$19M Part DDeclining
Post-LOE
Anchor product representing 33% of company revenue; mature generic with ongoing Part D utilization but exposed to biosimilar and generic competition pressure.
Help build intelligence for Cipla
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.